ArticleCancer immunology, immunotherapy : CII2025
Circ_0074158 and QKI6: A regulatory axis for PD-L1 ubiquitination and immune evasion in NSCLC.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review).International journal of molecular medicine · 2026Review
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveCircRNAs are involved in cancer progression. However, their role in immune escape in non-small cell lung cancer (NSCLC) remains poorly understood.
methodsThis study employed RIP-seq for the targeted enrichment of circRNAs, followed by Western blotting and RT-qPCR to confirm their expression. Specific binding was assessed using electrophoretic mobility shift assays. Transwell and wound healing assays were performed to evaluate the invasive and migratory capacities of NSCLC cells. The secretion of TNF-α, IFN-γ, GzmB, and perforin by CD8
resultsQKI6 modulates the level of PD-L1 ubiquitination in NSCLC. Both hsa_circ_0074158 and QKI6 influence the proliferation, invasion, and migration of NSCLC cells. Circ_0074158 regulates PD-L1 ubiquitination by modulating QKI6 expression, thus affecting PD-L1 expression. Furthermore, circ_0074158 activates CD8
conclusionThe circ_0074158/QKI6 axis regulates PD-L1 ubiquitination in NSCLC, limiting tumour cell proliferation and invasion. Our findings reveal a novel function for circ_0074158 in NSCLC, suggesting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.